# Analyzing the Optimal Treatment for Malaria Using the Artemisia annua


Dan Amirault- Biomedical Engineering Kayleah Griffen- Mechanical Engineering

#### Abstract

Malaria is a parasitic disease impacting 3 billion people worldwide. The *Plasmodium falciparum* is drug resistant to 90% of antimalarial compounds. Artemisinin is being used in a variety of forms to treat Malaria, and the best way is in edible tablets created from organic Artemisia annua.


### **Description of Treatments**











Glandular trichomes

Artemisinin is produced in the glandular trichomes of the A. annua.

### Project Goals/Objectives

Determine the ideal treatment for malaria derived from the A. annua by analyzing the benefits and costs of ACTs, pACT and transgenic A. annua.

### Why Malaria?

- Endangers 3 billion people worldwide
- 90% cases in Africa(2)
  - Injects the *Plasmodium*
- falciparum parasite (1) • **10%** reduction of GDP (1)

## **Analysis of Treatments**

#### **Sustainability**

Resistance

**Effectiveness** 















Artemisinin




ACT resistance rapidly compared to pACT (4)

#### **Social Acceptability**

**WHO** 

**Public** Acceptance













Delivery to

Body



pACTs already widely accepted in developing countries (4)

#### **Economic Feasibility**

**Production** Method

Cost


**Production** Location

















- pACT cost \$0.10-\$0.30 / treatment (4)
- ACT costs \$6 / treatment (6)
- pACT production could occur in developing country (4)
- ACT production is costly and nondomestic (6)


### Results and Discussion



- pACT= best treatment option
- Clonally propagated yields 1.4% Artemisinin content consistently (4)
- Least likely for drug resistance
- Already accepted in developing countries
- \$0.10-\$0.30/ treatment (4)
- Production occurs in developing country
- Method shown below









Ground Sieved Compressed

### Measures for Attribution

Analyze mortality rates and incidence rates of malaria recorded by the WHO. Analyze the economic impact on a country based on GDP. Analyze if socially acceptable by people by studying compliance.

### Acknowledgments

We would like to thank our professors Jill and Helen. We would also like to give a special thanks to Rebecca Zinno for her help with writing and research, Pamela Weathers for her insight on the A. annua, and Jim and Jess for their design skills.

#### References

- 1. Fosu, A. K., Mwabu, G., & Ebrary Academic Complete. (2007). *Malaria & poverty in africa*. Nairobi: University of Nairobi Press. 2. Jamison, D. T., NLM (National Library of Medicine) Gateway, World Bank, Disease Control Priorities Project, Ebrary Academic Complete, & Open Knowledge Repository. (2006). Disease control priorities in developing countries. New York: Oxford University Press. doi:10.1596/978-
- 3. Tang, K., Shen, Q., Yan, T., & Fu, X. (2014). Transgenic approach to increase artemisinin content in artemisia annua L. Plant Cell Reports, 33(4). 605-615. doi:10.1007/s00299-014-1566-y
- 4. Pamela Weathers. personal communication. November 12, 2014
- 5. Fairhurst, R. (2012). Artemisinin-resistant malaria: Research challenges,
- opportunities, and public health implications. *Public Health Resources,* Retrieved from DigitalCommons@University of Nebraska Lincoln Ladner, J., Sams, K., Tekinturhan, E., de Korte, D., & Saba, J. (2013). Artemisinin-based combination therapy availability and use
- in the private sector of five AMFm phase 1 countries. *Malaria Journal*, 12(1), 135.
- http://internationalmedicalcorps.org/image/diseases/mosquito.gif http://www.mediseeds.ch/wp-content/uploads/2008/11/artemisia-annua-rt72.jpg http://aobpla.oxfordjournals.org/content/2012/pls018/F2.medium.gif